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4 understood. The extent to which the effect of a CCB, ACEi, and an ά-blocker (as compared to a 1 diuretic) on incident HF is mediated by evolving LVH and blood pressure (BP) lowering per se 2 remains unknown. This study aimed to quantify the extent to which the effect of lisinopril, 3 amlodipine, and doxazosin (as compared to chlorthalidone) on incident HF is mediated by 4 evolving LVH and BP lowering. We hypothesized that evolving ECG LVH and BP lowering are 5 mechanisms behind previously observed differences in the rate of incident HF in hypertensive 6 ALLHAT participants randomized to lisinopril, amlodipine, and doxazosin, in comparison to 7 those randomized to chlorthalidone. 8
Methods 9
For this study, we used the ALLHAT dataset, publicly available from the National Heart, 10 Lung, and Blood Institute, via BioLINCC. The study was reviewed by an Oregon Health and 11 Science University Institutional Review Board and determined that it did not require further 12 review due to the de-identified nature of publicly available dataset. 13
Study population 14
The ALLHAT design and rationale have been described previously. 6 Briefly, ALLHAT 15 enrolled adults age 55 and above, with HTN and at least one risk factor [documented coronary 16 heart disease (CHD), type II diabetes mellitus, LVH on ECG or echocardiogram, smoking, high-17 density lipoprotein (HDL) < 35mg/dL, or ST-T ECG changes indicative of ischemia]. 18 Symptomatic HF patients or those with LVEF <35%, patients with recent myocardial infarction 19 (MI), stroke, or poorly controlled HTN were excluded. 20 In this study, we included ALLHAT participants with available assessment of evolving LVH 21 status, and dynamic BP changes. We excluded participants with missing covariates. Final study Covariates 1 Baseline BP was calculated as an average of two BP determinations taken at least one day 2 apart, with each determination being an average of 2 measurements. 3 Baseline ECG-LVH was based on any ECG within the past 2 years. definition included any one of the following: (1) R amplitude in V5 or V6 > 26 mm, (2) R 5 amplitude in V5 or V6 plus S amplitude in V1 > 35 mm, (3) R amplitude in aVL > 12 mm, (4) R 6 amplitude in Lead I > 15 mm, (5) R amplitude in Leads II or III, or aVF > 20 mm, (6) R 7 amplitude in Lead I plus S amplitude in Lead III > 25 mm, (7) R amplitude in aVL plus S 8 amplitude in V3 > 28 mm for men or > 22 mm for women, or (8) computerized ECG machine 9 documented LVH. 10
Echocardiographic LVH (Echo-LVH) was defined as combined wall (posterior wall plus 11 interventricular septum) thickness ≥ 25 mm on any echocardiogram in the past 2 years. 12
Baseline medical history was determined by the study investigators by a combination of chart 13 review and questioning during a routine office visit. HTN history determined whether 14 participants were treated for at least 2 months, were treated for less than 2 months, or were 15 untreated. History of MI or stroke was at least 6 months old. History of revascularization 16 included history of angioplasty, stenting, atherectomy, bypass surgery [coronary; peripheral 17 vascular; carotid; vertebrobasilar], or aortic aneurysm repair. Presence of major ST segment 18 depression or T wave elevation on any ECG in the past two years was identified. History of other 19 atherosclerotic cardiovascular disease (CVD) included documented peripheral artery disease or 20 cerebrovascular disease. Baseline CHD history included known prior MI (including silent MI), 21 angina, cardiac arrest, angiographically defined coronary stenosis more than 50%, reversible 22 perfusion defects on cardiac scintigraphy, or prior coronary revascularization procedures. Type II 23 diabetes was defined as fasting plasma glucose > 140 mg/dl [7.77 mmol/L] or non-fasting 1 plasma glucose > 200 mg/dl [11.1 mmol/L] in the past 2 years and/or current treatment with 2 insulin or oral hypoglycemic agents. History of HDL cholesterol < 35 mg/dl (0.91 mmol/l) on 3 any 2 or more determinations within past 5 years was included. History of smoking was also 4 obtained. 5
Statistical analysis 6
All continuous variables are presented as means±standard deviation (SD). ANOVA and χ 2 7 test was used for unadjusted comparison of clinical characteristics in participants with evolving 8 ECG-LVH. To determine association of clinical characteristics with achieved in-trial BP 9 changes, we used multivariable linear regression models, minimally adjusted for age, sex, and 10 race/ethnicity. Intention-to-treat (ITT) randomization assignment was used for definition of 11 antihypertensive treatment groups. 12
Minimally adjusted (by age, sex, and race/ethnicity) Cox regression models were used to 13 describe associations of baseline clinical characteristics, evolving ECG-LVH, and BP-lowering 14 with two different definitions of incident HF, for comparison. Associations between BP-lowering 15 (continuous variable) and HF risk were also evaluated using adjusted (as above) Cox regression 16 models incorporating cubic splines with 4 knots. 17
We conducted causal mediation analysis 14 , allowing for treatment-mediator interaction in the 18 logistic regression, using counterfactual definitions of direct and indirect effects, as implemented 19 by VanderWeele and colleagues. 15 Two models were estimated: a linear model for the mediator 20 conditional on treatment and covariates, and a logistic model for the outcome conditional on 21 treatment, the mediator, and covariates. Our study design is well-suited for mediation analysis, as 22 randomization eliminated exposure-outcome and exposure-mediator confounding. Two 23 mediators were studied (Figure 2): (1) evolving ECG-LVH, and (2) BP lowering over the course 1 of the trial. We adjusted for mediator-outcome confounders 11, 16 , which were measured at 2 baseline: demographic (age, sex, race and ethnicity) and clinical characteristics known to be 3 associated both with LVH/HTN and HF: common risk factors (body mass index [BMI], 4 smoking, diabetes), HTN history (levels of baseline systolic BP (SBP) and diastolic BP (DBP), 5 baseline use of antihypertensive medications, ECG-or echo-LVH), CHD or CVD history, 6 coronary revascularization, major ST depression or T-wave inversion, HDL<35 mg/dL twice in 7 the past 5 years, and participation in the lipid-lowering ALLHAT trial. A natural direct effect 8 represents the influence of antihypertensive treatment that is independent of evolving ECG-LVH 9 or BP-lowering, in the absence of evolving ECG-LVH or BP changes (e.g. via pleiotropic effects 10 or drug-specific pharmacodynamics). A controlled direct effect represents the effect of 11 antihypertensive drug at certain level of mediator (at progressing/resolving ECG-LVH with a 12 reference at absent evolving ECG-LVH, and at tertiles of BP changes), allowing measurement of 13 interaction between treatment and a mediator. A mediated effect represents the influence of 14 antihypertensive drug that can be explained by its influence on evolving ECG-LVH or dynamic 15 BP changes achieved over the course of the trial. To assess the extent of mediation, we estimated 16 the proportion mediated as a ratio of DE*(ME-1)/(DE*ME-1), where DE is direct effect and ME 17 is mediated effect. 18
Sensitivity analyses. To test robustness of our findings, we repeated analyses with different 19 definitions of BP lowering, expressed as: (1) fastest BP control; (2) relative greatest BP control; 20
(3) relative fastest BP control. 21 1 TX). Given the many multivariate and interaction analyses performed, statistical significance at 2 the 0.05 level should be interpreted cautiously. 3
Results 4

Study population 5
Study population (Table 2 ) was identical to previously reported ALLHAT population, 8, 9 6 maintaining treatment groups randomization ratio 1.7:1:1:1. After median 3.1 years follow-up in 7 doxazosin group, and 5.0 years in other 3 groups, there were 2,049 incident HF outcomes, 8 including 1,598 hospitalized/fatal HF outcomes. 9
Serial ECG changes: evolving ECG-LVH 10
Overall, 58,366 serial ECG changes were evaluated. ECG-LVH resolution was observed in 11 about 2% of participants, and in another 2% ECG-LVH progressed ( Table 2 ). The majority of 12 participants had no evolving ECG-LVH changes. ALLHAT participants with evolving ECG-13 LVH were more likely black males, current smokers with lower BMI, but less likely having 14 CHD/MI history. As expected, baseline ECG-LVH was more frequent in participants with 15 resolving ECG-LVH. Baseline LVH by echocardiogram was similar in all 3 groups, and was 16 very infrequent (4-5%). Participants with resolving LVH by ECG were more likely diabetic, less 17 likely to have been treated before the onset of the trial, and achieved the greatest degree of BP-18 lowering in-trial. Incident HF was significantly more frequent in participants with evolving 19 ECG-LVH (Table 2 ). Doxazosin and lisinopril ITT were more likely to be associated with 20 progressing ECG-LVH, and less likely associated with ECG-LVH reduction. In contrast, 21 chlorthalidone and amlodipine ITT were more likely to be associated with ECG-LVH reduction, 1 and less likely associated with ECG-LVH progression ( Table 2) . 2
Dynamic changes in Blood Pressure in-trial 3
The first (Q1), second (Q2), and third (Q3) tertiles of the greatest BP-lowering were -32/-4 19±10/6 mmHg, -11/-7±5/3mmHg, and +11/6±12/7 mmHg, respectively. Q1, Q2, and Q3 of the 5 fastest BP-lowering were -28/-16±10/6 mmHg, -7/-4±5/3 mmHg, and +14/8±12/6 mmHg, 6 accordingly. Hispanic ethnicity, previously untreated HTN, higher baseline levels of SBP/DBP 7 ( Figure 3 ) and baseline ECG-LVH were associated with greater SBP and DBP lowering in-trial 8 (Table 3 ). In contrast, presence of diabetes was associated with a SBP increase of nearly 2 9 mmHg. Older age was associated with greater SBP-lowering but slight DBP-increase. History of 10 CHD/CVD did not affect the degree of BP-lowering in-trial. Compared to chlorthalidone, 11 doxazosin was associated with significant SBP increase (by nearly 2 mmHg), whereas 12 amlodipine was associated with significant SBP and DBP decrease. Lisinopril was associated 13 with greater DBP (but not SBP) lowering than chlorthalidone (Table 3) . Participants in the 14 doxazosin arm who developed HF had the greatest degree of BP-lowering (both SBP/DBP) in-15 trial (~6/2 mmHg lower than by diuretic), which contrasted with overall weak BP-lowering 16 effect of doxazosin in the trial (Table 3) . 17
Risk factors for Heart Failure 18
As expected, age, ethnicity, history of HTN, CHD, and CVD, as well as ECG-LVH were 19 associated with increased risk of HF (Table 4 ). There were very little differences between risk 20 factors of two incident HF outcomes: incident symptomatic HF and hospitalized/fatal HF. 21 1 LVH carried larger risk, as compared to resolving ECG-LVH. Evolving LVH was associated 2 with incident HF in three out of four treatment groups (Pinteraction=0.056; Figure 5 ). 3
The association of in-trial BP changes with HF was non-linear ( Figure 6 ). Both large 4 decrease and poor control of BP were associated with incident HF, but large decrease in BP had 5 a stronger effect than poor BP control on both primary and secondary outcomes (Table 4) . A 6 similar association of SBP-lowering with incident HF was observed in three out of four treatment 7 groups (Figure 7 ). In the amlodipine treatment group, SBP change was not associated with 8 incident HF (Pinteraction=0.039; Figure 6 ). A noticeable U-shaped association of DBP-change with 9 incident symptomatic HF was observed in the amlodipine and chlorthalidone treatment groups 10 ( Figure 8 ), whereas poor DBP control in the lisinopril and doxazosin treatment groups was not 11 associated with incident HF. 12
Mediation of HF risk by evolving LVH 13
In fully adjusted analyses, evolving LVH mediated 4% of the effect of doxazosin on HF 14 (Table 5 ). Both direct and mediated pathways contributed to the increased HF risk in doxazosin 15 arm. The effect of amlodipine and lisinopril on HF was entirely independent of evolving LVH. 16
Mediation of HF risk by dynamic BP changes 17
After full adjustment for confounders, SBP-lowering mediated 12% of the effect of 18 doxazosin on HF (Table 5 ). Of note, the direct and mediated effects of doxazosin on HF were in 19 opposite directions: direct effect of doxazosin increased HF risk, whereas SBP-lowering-20 mediated effect reduced HF risk by 12%. There was significant (P<0.0001) interaction between 21 doxazosin treatment and mediator: SBP-lowering in Q1 and Q2 was associated with increased risk of HF, whereas Q3 SBP change (mean increase 11 mmHg) was protective. The effects of 1 amlodipine and lisinopril on HF were entirely independent of SBP changes. 2 DBP-lowering mediated 10% of the effect of doxazosin, and 7% of the effect of amlodipine, 3 and 9% of the effect of lisinopril on HF. In fully adjusted analyses (Table 5 ) mediation of the 4 effect of lisinopril lost statistical significance. Both direct and mediated pathways had the same 5 direction and contributed to the increased HF risk. 6
Sensitivity analyses with different definitions of BP-lowering provided similar results ( Table  7 6). The fastest SBP-lowering mediated ~13% of the effect of lisinopril on HF. 8
Discussion 9
The main finding of our study is that the evolving ECG-LVH and BP-lowering explain up to 10 13% of the HF-preventive effect of diuretic chlorthalidone, as compared to the preventive effect 11 of antihypertensive treatment with the alpha-blocker doxazosin, the ACEi lisinopril, and the 12 CCB amlodipine. This finding highlights the notion of HF as a complex multifactorial condition, 13 and underscores importance of the use of diuretics for HF prevention, which targets mechanisms 14 that are largely independent of BP-lowering and evolving ECG-LVH. 15
Heart failure prevention in hypertension 16
HTN is the major risk factor of HF, associated with 2-3 fold increased HF incidence in 17 observational cohort studies. 17 However, RCTs HTN treatment is associated with only 20-25% 18 reduction in HF risk 5 . Our study provided consistent findings: BP-lowering mediated only up to 19 13% effect of antihypertensive medications on incident HF. Such disconnect between a risk 20 factor and effect of its modification is traditionally explained by poor BP control, irreversible 21 damage of the heart over long-time risk exposure, insufficient awareness of HTN, and inadequate assessment of HTN by a single BP measurement. Our study findings suggest that in 1 order to achieve the most effective HF prevention, BP-lowering should not be the only criterion 2 of HTN treatment effectiveness. Moreover, as different antihypertensive treatments have 3 different mediators, different criteria of effectiveness (beyond BP-control) should be developed 4 for each class of antihypertensive drugs. 5
Diuretics for HF prevention 6
Our study showed that mechanisms by which the thiazide diuretic chlorthalidone prevented 7 HF were not restricted to BP-lowering and prevention of LVH. The mechanisms responsible for 8 favorable effect of chlorthalidone on HF prevention in HTN persons are unknown. In addition to 9 BP-lowering, chlorthalidone has pleotropic effects, including improving endothethial function 10 and reducing inflammation and oxidative stress). 18 Better understanding of the mechanisms 11 behind the effect of chlorthalidone on HF may lead to new drug formulations, specifically 12 targeting HF prevention in patients with HTN. 13
Left ventricular hypertrophy and heart failure 14
Longstanding HTN and LVH can start a devastating cascade that leads to HF via myocyte 15 growth, oxidative stress, and fibrosis. 19 While antihypertensive drugs have been shown to reduce 16 and even reverse LVH, this study showed that reduction in ECG-LVH increased the risk of HF, 17 as compared to patients who remained free from LVH. 18
In the current study, evolving LVH mediated only 4% of the effect of doxazosin on HF. 19 Consistent with our findings, previous analysis of Cornell voltage changes during the ALLHAT 20 trial 20 showed no difference in ECG-LVH development/resolution between the amlodipine, 21 lisinopril, or chlorthalidone treatment arms. There are known limitations of ECG-LVH as a 22 measure of the LV enlargement, as there are more than a dozen ECG-LVH definitions with poor 23 agreement among them. 21 Differences between LVH measured by ECG vs. LV mass measured 1 by imaging modalities 21 reflect true differences between the cardiac anatomy and the 2 electrophysiological substrate. ECG-LVH characterizes an abnormal electrophysiological 3 substrate, which is associated with sudden cardiac death and incident HF independent of LV 4 mass and BP control [22] [23] [24] should be taken into account. While we adjusted for known common causes of evolving ECG-7 LVH, BP-lowering, and incident HF, unmeasured confounding can affect this study estimates. 8
ALLHAT enrolled high-risk HTN patients, and results of this study may not be generalizable to 9 a lower-risk populations. In our study, baseline BP displayed moderate correlation with in-trial 10 BP-lowering (Figure 3 ), which at least partially explained U-shaped association of BP-lowering 11 with incident HF. While we utilized modeling approaches accounting for non-linear associations, 12 it is possible that we under-estimated true effect of BP-lowering on incident HF. 13
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Leads Change Criteria
Progressing ECG-LVH 3-0 3-1 (significant increase; E-LVH1) I, II, III +36% 3-0 3-1 (significant increase; E-LVH1) aVL Increase >60% 3-0 3-1 (significant increase; E-LVH1) V5/V6 Increase >30% 3-0 3-3 (significant increase; E-LVH2) I Increase >36% 3-0 3-3 (significant increase; E-LVH2) V5/V6 Increase >25% 3-1 3-1(significant increase; E-LVH5) I, II, III +36% 3-1 3-1(significant increase; E-LVH5) aVL +60% 3-1 3-1(significant increase; E-LVH5) V5/V6 +30% 3-3 3-3(significant increase; E-LVH6) I +36% 3-3 3-3(significant increase; E-LVH6) V5/V6 +25% RR=relative risk. Proportion mediated=DE*(ME-1)/(DE*ME-1), where DE is direct effect and ME is mediated effect. Q1, Q2, Q3 = tertiles of blood pressure change. A controlled direct effect represents the effect of a drug at certain level of mediator (at absent evolving ECG-LVH/ progressing/ resolving ECG-LVH, and at tertiles of BP changes), allowing measurement of interaction between treatment and a mediator. 
